برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️(artesunate) for Injection Date of Approval: May 26, 2020 Company: Amivas (US), LLC Treatment for: Malaria Artesunate for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients. https://t.me/ppdprogram

➡️Kynmobi (apomorphine hydrochloride) Sublingual Film Date of Approval: May 21, 2020 Company: Sunovion Pharmaceuticals Inc. Treatment for: Parkinson's Disease Kynmobi (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine for the on-demand management of OFF episodes associated with Parkinson’s disease (PD). https://t.me/ppdprogram

➡️Qinlock (ripretinib) Tablets Date of Approval: May 15, 2020 Company: Deciphera Pharmaceuticals, Inc. Treatment for: Gastrointestinal Stromal Tumor Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. https://t.me/ppdprogram

➡️Retevmo (selpercatinib) Capsules Date of Approval: May 8, 2020 Company: Eli Lilly and Company Treatment for: Non-Small Cell Lung Cancer, Thyroid Cancer Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. https://t.me/ppdprogram

➡️Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection Date of Approval: May 1, 2020 Company: The Janssen Pharmaceutical Companies of Johnson & Johnson Treatment for: Multiple Myeloma; Light Chain (AL) Amyloidosis Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab (a CD38-directed cytolytic antibody) and hyaluronidase (an endoglycosidase) indicated for the treatment of multiple myeloma and light chain (AL) amyloidosis. https://t.me/ppdprogram

➡️Bafiertam (monomethyl fumarate) Delayed-Release Capsules Date of Approval: April 28, 2020 Company: Banner Life Sciences LLC Treatment for: Multiple Sclerosis Bafiertam (monomethyl fumarate) is a novel fumarate indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. https://t.me/ppdprogram

➡️Ongentys (opicapone) Capsules Date of Approval: April 24, 2020 Company: Neurocrine Biosciences, Inc. Treatment for: Parkinson's Disease Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. https://t.me/ppdprogram

➡️Tukysa (tucatinib) Tablets Date of Approval: April 17, 2020 Company: Seattle Genetics, Inc. Treatment for: Breast Cancer Tukysa (tucatinib) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer. https://t.me/ppdprogram

➡️Jelmyto (mitomycin) for Pyelocalyceal Solution Date of Approval: April 15, 2020 Company: UroGen Pharma Ltd. Treatment for: Urothelial Carcinoma Jelmyto (mitomycin) is a novel formulation of the approved alkylating drug mitomycin for the treatment of patients with low-grade upper tract urothelial cancer (LG-UTUC). https://t.me/ppdprogram

➡️Koselugo (selumetinib) Capsules Date of Approval: April 10, 2020 Company: AstraZeneca and Merck Treatment for: Neurofibromatosis Type 1 Koselugo (selumetinib) is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). https://t.me/ppdprogram

➡️Sevenfact (coagulation factor VIIa (recombinant)-jncw) Injection Date of Approval: April 1, 2020 Company: HEMA Biologics, LLC Treatment for: Hemophilia A or B with Inhibitors Sevenfact (coagulation factor VIIa [recombinant]-jncw) is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies). https://t.me/ppdprogram

➡️Zeposia (ozanimod) Capsules Date of Approval: March 25, 2020 Company: Bristol-Myers Squibb Company Treatment for: Multiple Sclerosis, Ulcerative Colitis Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; and moderately to severely active ulcerative colitis (UC) in adults. https://t.me/ppdprogram

➡️Durysta (bimatoprost) Implant Date of Approval: March 3, 2020 Company: Allergan plc Treatment for: Glaucoma, Open Angle, Intraocular Hypertension Durysta (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT). https://t.me/ppdprogram

➡️Advil Dual Action (ibuprofen and acetaminophen) Tablets Date of Approval: February 28, 2020 Company: GSK Consumer Healthcare Treatment for: Pain Advil Dual Action (ibuprofen with acetaminophen) is an over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug (NSAID) contained in Advil) and acetaminophen (the active ingredient in Tylenol) for the relief of pain. https://t.me/ppdprogram

➡️Nurtec ODT (rimegepant) Orally Disintegrating Tablets (ODT) Date of Approval: February 27, 2020 Company: Biohaven Pharmaceutical Holding Company Ltd. Treatment for: <a href="https://www.drugs.com/condition/migraine.html">Migraine</a>; <a href="https://www.drugs.com/condition/migraine-prophylaxis.html">Migraine Prophylaxis</a> Nurtec ODT (rimegepant) is an orally-dosed calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraine with or without aura, and the preventive treatment of episodic migraine, in adults. https://t.me/ppdprogram

➡️Barhemsys (amisulpride) Injection Date of Approval: February 26, 2020 Company: Acacia Pharma Treatment for: Nausea/Vomiting, Postoperative Barhemsys (amisulpride) is a dopamine-2 (D2) antagonist for the management of post-operative nausea and vomiting (PONV). https://t.me/ppdprogram

➡️Nexletol (bempedoic acid) Tablets Date of Approval: February 21, 2020 Company: Esperion Therapeutics, Inc. Treatment for: High Cholesterol, Familial Heterozygous Nexletol (bempedoic acid) is a first-in-class, adenosine triphosphate-citrate lyase (ACL) inhibitor for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-Cholesterol. https://t.me/ppdprogram

➡️Pizensy (lactitol) Powder for Oral Solution Date of Approval: February 12, 2020 Company: Braintree Laboratories, Inc. Treatment for: Chronic Idiopathic Constipation Pizensy (lactitol) is an osmotic laxative indicated for the treatment of chronic idiopathic constipation (CIC) in adults. https://t.me/ppdprogram

➡️Gloperba (colchicine) Oral Solution Date of Approval: January 30, 2019 Company: Romeg Therapeutics, LLC Treatment for: Gout Gloperba (colchicine) is an oral solution formulation of the approved drug colchicine indicated for prophylaxis of gout flares in adults. https://t.me/ppdprogram

➡️Wixela Inhub (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 30, 2019 Company: Mylan N.V. Treatment for: Asthma, COPD Wixela Inhub (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub is the first approved generic version of Advair Diskus. https://t.me/ppdprogram